{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:07:34Z","timestamp":1648840054764},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1097\/rhu.0b013e31821d479d","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T17:57:45Z","timestamp":1355767065000},"page":"S11-S12","source":"Crossref","is-referenced-by-count":0,"title":["A New Standard of Care? Studies on Febuxostat in the Management of Hyperuricemia With and Without Gout"],"prefix":"10.1097","volume":"17","author":[{"given":"Kamatani","family":"Naoyuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosoya","family":"Tatsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210207","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R2-1-20210207","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/ar2761","article-title":"Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?","volume":"11","author":"Gaffo","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R3-1-20210207","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"R4-1-20210207","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R5-1-20210207","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R6-1-20210207","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"R7-1-20210207","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R8-1-20210207","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0091270008322035","article-title":"The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.","volume":"48","author":"Khosravan","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R10-1-20210207","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R11-1-20210207","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0300-2977(97)00088-0","article-title":"The allopurinol hypersensitivity syndrome.","volume":"52","author":"Pluim","year":"1998","journal-title":"Neth J Med"},{"key":"R12-1-20210207","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","article-title":"International position paper on febuxostat.","volume":"29","author":"Jansen","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R13-1-20210207","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective.","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R14-1-20210207","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares. Analysis from managed care data.","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R15-1-20210207","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R16-1-20210207","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R17-1-20210207","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R18-1-20210207","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R19-1-20210207","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R20-1-20210207","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e31821d479d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:55:58Z","timestamp":1620971758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201106002-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31821d479d","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}